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Abstract
BACKGROUND—Preterm infants with RDS given inositol had reduced BPD, death and severe 
ROP. We assessed the safety and pharmacokinetics(PK) of daily inositol to select a dose providing 
serum levels previously associated with benefit, and to learn if accumulation occurred when 
administered throughout the normal period of retinal vascularization.
METHODS—Infants ≤29wks GA (n=122, 14 centers) were randomized and treated with placebo 
or inositol at 10, 40 or 80mg/kg/day. Intravenous administration converted to enteral when 
feedings were established, and continued to the first of 10 weeks, 34weeks PMA or discharge. 
Serum collection employed a sparse sampling population PK design. Inositol urine losses and 
feeding intakes were measured. Safety was prospectively monitored.
RESULTS—At 80mg/kg/day mean serum levels reached 140mg/L, similar to Hallman’s findings. 
Levels declined after 2 weeks, converging in all groups by 6 wks. Analyses showed a mean 
volume of distribution 0.657 L/kg, clearance 0.058 L/kg/hr, and half-life 7.90 hr. Adverse events 
and co-morbidities were fewer in the inositol groups, but not significantly so.
CONCLUSIONS—Multiple dose inositol at 80mg/kg/day was not associated with increased 
adverse events, achieves previously effective serum levels, and is appropriate for investigation in a 
Phase 3 trial.
INTRODUCTION
Retinopathy of Prematurity is a common problem worldwide among preterm infants, often 
leading to vision impairment or blindness(1). Hallman reported two trials of postnatal 
inositol treatment of preterms with RDS to support phosphatidylinositol in surfactant 
synthesis, and both trials demonstrated improved RDS and a lower incidence of death or 
BPD, and ROP(2,3). Inositol is an important component of surfactant, and essential 
intracellularly as phosphoinositides. Howlett concluded in a Cochrane meta-analysis of 
inositol in preterm infants, “that a multi-center, randomized controlled trial of appropriate 
size is warranted to confirm these findings”(4). We reported the PK of a single dose of IV 
inositol in preterm infants at doses of 60mg/kg or 120mg/kg, and found the half-life was 
5.22hr, with large urine losses, particularly in the first 12hr after dosing(5). Our 3 goals were 
to identify a daily dose to achieve serum levels similar to those reported by Hallman, 
[170mg/L (994μmole/L) at 8–9 days for infants given 160mg/kg/day, and an approximate 
mean value over the first week of life of 135mg/L (750μmole/L) when receiving 80mg/kg/
day(2,6)]; to learn if divided doses would reduce urine losses; and to assure safety with up to 
10 weeks of treatment. We examined the safety and PK of inositol given at 3 dose levels 
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compared to placebo for up to 10wks, both IV and enteral (#NCT01030575). This time 
frame was chosen to support inositol levels throughout the post-preterm delivery period 
when most retinal vessel growth normally occurs within the high inositol, in-utero 
environment(7,8).
RESULTS
From January to October 2010, 125 infants ≤29weeks gestation were randomized and 122 
received treatment during the time for the designed 96 infants to complete the protocol 
(Figure 1). The mean gestation was 26 weeks, and baseline characteristics were similar 
across groups (Table 1). Study drug was received for 42–51 days, and 43–57% of doses were 
IV. The number of missed or held doses was similar across groups (average of 1 to 3 per 
subject).
Safety Outcomes
At least one adverse event of moderate or greater severity occurred in 104 infants, and the 
average number/subject (5.5 to 5.7) was similar across treatment groups (Supplementary 
Table S1 (online)). No specific type of event occurred more frequently in the inositol groups 
compared to the placebo group. Per protocol, inositol doses were held for severe oliguria 
(renal losses of inositol are large enough that oliguria could have led to high serum inositol 
levels). This occurred in 5 infants on placebo and 2, 4, and 3 infants in the 10, 40 and 
80mg/kg/day groups, respectively. Of these, 8 infants resumed study drug after recovery, 4 
discontinued study drug permanently (1, placebo; 1, 10mg/kg/d; and 2, 80mg/kg/d), and 2 
expired (both in the 40mg/kg/d group). Comparing adverse event rates in placebo vs all 
inositol, or across the dose groups, p-values were all >0.05 with most >0.10.
Serious adverse events (severe, life threatening or fatal) were common in this population 
(Table 2), but no specific types occurred more frequently in the inositol groups compared to 
placebo. Clinical diagnoses are listed in Table 3, and all 15 deaths occurred in the 23–26 
week GA stratum. Infection was reported as a primary cause of death in the 40mg/kg group 
for 17% of subjects; compared to 0–3% as the cause of death for other dose groups (p<0.01 
for comparing across all dose groups). No diagnoses had p-values <0.05 when comparing 
across the treatment groups (Table 3). However, intraventricular hemorrhage (any IVH, as 
well as grades III/IV) occurred more frequently in the 0 and 40 groups than in the 10 and 80 
groups (p=0.05 for IVH III/IV). Failing the discharge hearing screening in either ear 
occurred more often in the 40 or 80mg/kg/day inositol groups (20% and 14%, respectively) 
than in the 0 and 10mg/kg/day groups (4%), (p=0.25).
Severe ROP meeting criteria for surgery, or receiving intervention for ROP occurred among 
the surviving infants examined in 19% of the placebo group and in 12%, 8%, and 9% of the 
10, 40, and 80mg/kg/day inositol groups, respectively (p=0.72). The planned Phase 3 study 
primary outcome of meeting criteria for ROP surgery, or death before ROP outcome, among 
those infants eligible for that trial (<280/7 weeks GA) was highest in the placebo group and 
lower in the inositol groups (44%, 23%, 36%, and 19%, for the placebo, 10, 40, and 
80mg/kg/day groups, respectively, p=0.29). Results including the six adjudicated ROP 
outcomes were similar: 41%, 22%, 36% and 16%, respectively.
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Growth (weight, head circumference, length) was examined using z-scores to adjust for 
PMA, and these parameters did not significantly differ across groups. An average of 15 
concomitant medications were received while on study drug (range 3 to 34) and the number 
of courses of medication was similar across the 4 dose groups (average 19 courses, range 3–
67). The 10 most frequent concomitant drug exposures by study group did not reveal a 
particular pattern (Supplementary Table S2 (online)).
Serum Inositol
Mean serum levels were elevated in a dose-related manner in the early weeks (Figure 2, 
panel A); however by 6 weeks, the differences were minimal. To explore an effect of 
changing from IV to enteral drug, serum levels were plotted separately for samples obtained 
while infants were on IV drug (Figure 2, panel B), and while on enteral drug (Figure 2, 
panel C). Serum levels continued to decrease with age with either drug route, and once IV 
doses ended, mean levels over 75mg/L (416μM) were rare.
Inositol intake from feedings (calculated from the measured inositol levels and daily 
volumes of each type of feeding) rose from an average of 4mg/kg/day in week 1, to 40 – 
50mg/kg/day by week 6, and did not differ significantly across groups (data available from 
authors). There was no evidence of inositol accumulation in the serum with continued 
treatment at 80mg/kg/day, despite the additional intake of inositol from full enteral feeds.
Pharmacokinetics
The PK analysis initially considered a three-part model with components for the (i) 
combined effects of endogenous synthesis of inositol and inositol from feeding, (ii) initial IV 
administration and (iii) the shift to enteral administration. The enteral administration portion 
of the analysis used a multiple-administration, first-order absorption with linear elimination 
model including terms for bioavailability and a lag time prior to the start of absorption. 
However, it was not possible to estimate the third part of the model related to enteral 
administration. As noted in relation to Figure 2, it appears that as an infant matures, and is 
more likely to receive enteral inositol, the serum concentration is less affected by exogenous 
administration. The remainder of the PK analysis focused on the first two parts of the 
inositol serum concentration model.
The final PK analysis used data from two sources. The data from the current study were 
limited to observations obtained prior to the first enteral administration of inositol (Figure 2, 
panel B). The data thus correspond to observations related to the multiple IV administrations 
and are referred to as the multiple-administration dataset. The single-dose data previously 
analyzed were included in parts of the analysis and will be referred to as the single-
administration dataset(5). Both studies were conducted by the same investigators in the same 
research network using protocols consistent across both studies except for the repeated 
dosing.
For both datasets, a constant variance for the residual error fit best. Also, the relationships 
between the random effects were graphically studied by plotting uVi vs. uCli, uVi vs. uRi and 
uCli vs. uRi for all infants (see definitions in Methods section). A strong linear relationship 
was observed between the random-effects estimates for clearance (Cl) and endogenous 
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production rate (R) with no apparent relationship between the other two combinations of 
random effects. The random effects were then modeled only with the correlation between Cl 
and R.
Table 4 presents the Pop-PK estimates for the IV administration model including the 
apparent endogenous infusion rate. Derived values for the elimination rate, the half-life, and 
the apparent concentration associated with endogenous synthesis are also shown. This is 
done for three available sets of data, the single IV administration column as previously 
published, the multiple IV administration column from fitting the model to the new multiple-
administration dataset, and the last column from fitting the model to the combined 
datasets(5). The three sets of results are very consistent, with the combined results 
intermediate to the single and multiple-administration results. The half-life estimates range 
from the 5.22hr for the single-administration data to 7.90hr for the multiple-administration 
data, with the combined data estimate being 6.31hr. The random effect variance and 
correlation estimates are shown in Table 5 for the combination single-and multiple-
administration data. Plots of the actual versus individual predicted values were examined 
(not shown) and the values were well aligned, indicating the model provided a good fit to the 
data. In addition, plots comparing the individual predicted residuals versus the actual values 
did not indicate any major model deficiencies.
Twenty four hour urine inositol losses were determined at the end of weeks 1, 2, 4 and 5 to 6 
(Figure 3). At week one, mean urine losses were close to, or greater than the dose received, 
despite dividing doses q 12hr to lower peak serum levels. Week 1 excretion rates in the 80 
mg/kg group were similar to the observed 24hr excretion following a single dose of 
120mg/kg in week 1, previously published(5). At all ages, the mean inositol excretion was 
highest in the 80mg/kg/day group, falling from 107mg/kg/24hr at week 1, to 68mg/kg/24hr 
at weeks 5–6. There was no evidence of a diuretic effect of inositol as urine volumes 
measured between 3 and 5 ml/kg/hr and did not vary significantly by group (data not 
shown).
DISCUSSION
Inositol at 80mg/kg/day in low gestation infants was effective in reaching serum levels 
similar to those achieved during previous trials, and importantly, these levels did not 
continue to rise with dosing throughout the period of rapid retinal vascular development up 
to 10 weeks (approximately 34 weeks PMA)(9). There was no significant evidence of harm 
at any dose during the study, but prospective monitoring of hearing and infection should be 
conducted in future trials. Although not statistically significant with these small sample 
sizes, several co-morbidities appeared less frequent in the treated groups, which is reassuring 
in consideration of a Phase 3 trial.
The PK were best described by a 1-compartment multiple dose IV infusion model with 
linear elimination combined with apparent endogenous production for the periods of time 
when infants were receiving IV administration. While an expanded model was considered 
that included both IV infusion and enteral administration, we were unable to get a single 
model to converge for both the IV and enteral portions of the PK study. Brown, et. al. 
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reported the turnover rate of inositol using dual labeled stable isotopes to be approximately 
150–250mg/kg day in 33–34 weeks GA infants, a value consistent with the data that inositol 
is endogenously synthesized, as well as catabolized in the kidney(10,11). The inositol 
oxidase enzyme, unique to the renal cortex, catabolizes inositol to glucuronic acid and 
becomes active in the weeks after birth in the term newborn, likely contributing our finding 
of decreasing inositol in the urine despite ongoing treatment plus increasing inositol from 
feeds(12).
Inositol is necessary for phosphatidylinositol surfactant synthesis, which predominates over 
phosphatidylglycerol in preterm infants. Infants unable to receive human milk or formula 
feedings experience falling serum inositol levels. While supplementation may improve RDS 
and reduce both BPD and ROP, the effect on ROP was unexpected, and it is possible inositol 
was sufficiently effective in reducing pulmonary morbidity that it lowered the risk for ROP 
as a secondary effect by reducing oxygen exposure(2,3). However, phosphoinositides, 
inositol polyphosphates and inositol phosphoglycerols serve as signaling molecules in a 
number of intracellular events, and are essential factors in the chain of mediators leading to 
vascular growth, including VEGF, and insulin-like growth factor (IGF-1) (7,8,13). 
Therefore, inositol or its derivatives may be rate limiting in the roles of VEGF, IGF-1, or 
other factors critical to retinal vascular development which normally occurs in-utero from 14 
to 36 weeks gestation. If inositol is permissive for sustaining the health of retinal endothelial 
cells during this time period, it may explain why infants with low inositol levels in the early 
neonatal period are at higher risk for ROP(14). Metabolism of inositol is complex and not 
fully understood, changing in utero, with birth, and affected by enteral intake and complex 
endogenous controls that are likely developmentally regulated(7). Nonetheless, in early 
trials, inositol treatment appears safe and beneficial in preterm infants.
CONCLUSIONS
These data add to the evidence that inositol at doses up to 80mg/kg/day for 7–10 weeks is 
well tolerated and does not increase adverse events. As recommended in the Cochrane 
Review, the data on inositol supplementation warrants a large Phase 3 clinical trial to test its 
safety and efficacy to improve survival without severe ROP(4).
METHODS
Study Design
A randomized double-masked Phase 2 clinical trial was conducted in 14 centers of the 
Eunice Kennedy Shriver NICHD Neonatal Research Network(NRN). The study design was 
approved by the FDA and registered on clinicaltrials.gov (#NCT01030575). The protocol 
was approved by the NRN Data Safety Monitoring Committee and the IRB from each 
institution, and each subject’s parent or guardian provided written informed consent.
Population—Subjects were 230/7 to 296/7 weeks GA who weighed at least 400g, and could 
receive study drug by 72hr after birth. Exclusions included death before 12hrs, major 
congenital anomalies, severe oliguria, or a moribund state. Eligible infants were randomized 
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and stratified within center by gestational strata (230/7–266/7 vs. 270/7–296/7wks), to placebo 
or one of 3 daily doses of inositol.
Study Drug—Myo-inositol 5% Injection was provided by Abbott Nutrition, Columbus, 
OH as an isotonic, preservative and pyrogen-free, sterile, 5% solution of myo-Inositol IV at 
neutral pH. Doses were 10, 40, or 80mg/kg/day, divided q12hr given over 20minutes. 
Placebo was 5% glucose USP for IV infusion and dispensed at the equivalent various 
volumes to maintain masking. Randomization was by central computer, communicated to 
the research pharmacists who prepared doses of inositol or placebo in the pharmacy, 
dispensed as unit doses. Thus research and clinical personnel, and families remained masked 
to treatment assignment. When enteral feedings reached at least 100mL/kg/day (or the infant 
no longer was receiving IV fluids), the study drug was given enterally as the same 
formulation, at the same per kg dose. Study drug continued until 10 weeks chronologic age, 
34 weeks PMA, death, or discharge.
Individual infants contributed 8–10 scheduled serum samples over the 10 weeks 
(Supplementary Design Table S3 (online)). Sampling times were assigned so that 
approximately 8 samples were collected in each of the specified time frames for each dose 
group. Collection times were divided within each time window to collect peak, trough, and 
mid-dose samples. The time of each sample and the starting time of the preceding drug 
infusion were recorded. Additional measurements from scavenged serum or plasma with 
known times of collection (left over from laboratory studies ordered for usual care) were 
also processed, if available, with consent.
A 24hr urine collection was obtained at the end of weeks 1, 2, 4, and 6 (or 5 if being 
discharged). The change of diaper weight (dry to wet) was used as the best estimate of void 
volume where one gram=one ml. Urine was expressed from each wet diaper separately 
during the collection period, and an aliquot frozen(15). The time of each diaper-on and 
diaper-off were recorded.
Enteral feeds—Volume and sources (human milk, fortified human milk, or specific 
formulas) were recorded daily until intake was 100ml/kg/day for at least 7 days, and then 
were recorded weekly. Inositol concentrations were sampled from human milk actually 
given to the infant in the same week, unless insufficient volume was available. Formula 
inositol concentrations were measured twice from the stock of each type of formula the 
infant received, and re-assayed if the formula was then fortified. Inositol from milk feedings 
was calculated by summing the daily inositol intake from the volume ingested of each milk, 
multiplied by the measured inositol concentration for that milk.
Assay—myo-Inositol was measured with a validated assay on 25 or 50μl samples of serum, 
plasma, urine and milks, utilizing a multiple-column, multiple mobile phase liquid 
chromatographic system with electrochemical detection(15).
Clinical Outcomes
Adverse events were prospectively monitored from 24hrs prior to study drug until 7 days 
following the final dose (unless discharged sooner), and judged according to a neonatal 
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toxicity table developed for the study. Concomitant medications were recorded from 24hr 
prior to the start of study drug until 7 days following its final dose, unless the infant was 
discharged sooner. Weight, length, and head circumferences were measured prospectively.
Retinopathy outcomes were determined from the clinical eye examinations(16). The primary 
examining ophthalmologist at each center was trained and certified on the International 
Classification of ROP as used in 2006(17). An unfavorable outcome was defined as either 
Type 1 ROP or worse, in either eye, or surgical intervention for severe ROP in either 
eye(18). A favorable ROP outcome was assigned if the retinal vessels progressed to full 
vascularization in both eyes without meeting criteria for severe ROP, or if on two 
consecutive examinations the retinal vessels were in zone III(16). Examinations were 
continued, if necessary, up to 55 weeks PMA (3 months after term due date)(19,20). Infants 
who did not meet either criterion had all available examinations reviewed by an adjudication 
committee.
Co-morbidities were recorded prospectively using the established definitions of the NRN 
Generic Database Protocol(21). At 18–22 months corrected age, infants received a set of 
standardized examinations of neurologic function and development according to the NRN 
Follow Up Protocol (to be reported separately)(22).
Statistical Analyses
Sample size—Enrollment was continued until at least 48 infants in each of the two GA 
strata had completed a minimum of 28 days on study drug and contributed at least 5 serum 
samples. Infants were enrolled and randomized during the time when waiting to document 
that 96 infants had completed the protocol. All infants beginning treatment were permitted to 
complete the protocol, and all available data are included in the final analyses. Population 
PK studies typically target 6–8 samples at each of the time points to describe the change in 
serum concentrations(23,24). No formal power calculations were conducted because no 
formal hypotheses were to be tested in this Phase 2 study, and the analyses are exploratory 
and descriptive in nature.
Data obtained within the study assessment windows were all used. While the primary 
analyses were conducted without imputation for missing ROP data due to loss to follow-up 
or indeterminate final status, additional exploratory analyses were conducted to assess the 
impact of the missing data on the estimates of ROP. Adjudication was conducted by a 
committee of three experienced ophthalmologists not involved with the study and masked to 
study group assignment. They were provided data on the infant’s GA, birth weight, and each 
available eye examination, including age (chronologic and PMA) at each exam. The final 
ROP status was judged separately in each eye as ‘probably favorable’, ‘probably 
unfavorable’ or ‘cannot be determined’, and the majority classification was assigned as the 
adjudicated outcome.
Baseline characteristics and co-morbidities for all randomized and treated infants were 
compared by testing the null hypothesis of equality across all 4 dose groups using ANOVA 
for continuous measures, Mantel-Haenszel mean score tests (using modified ridit scores) for 
ordinal measures, and chi-square or Fisher’s exact test for nominal measures.
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Methods for Pharmacokinetic Analyses
In recognition of the relatively sparse sampling design for the collection of serum samples, 
population PK(Pop-PK) models were fit to the data using the nonlinear mixed effects 
approach in Monolix 3.2, manufacturer LIXOF, Antony, France. This approach accounts for 
the variability between infants in the model parameters, the correlation between 
measurements in the same infant at different occasions, as well the residual unexplained 
variability in serum concentrations(25). Two issues dictated the structure of the Pop-PK 
models that were considered for modeling the data from the study: 1) endogenous synthesis 
of inositol by the infants and inositol contained in feedings of human milk or infant formula; 
and 2) initial IV administration of inositol.
Endogenous synthesis and feeding intake of inositol were modeled in the same way as the 
single dose PK analyses(5). The steady state endogenous concentration for the ith infant is 
modeled as Ei = Ri/Cli where Ri is the apparent rate of inositol infusion due to the 
combination of endogenous synthesis and feeding, and Cli is the clearance. It is not possible 
to separate endogenous synthesis and feeding intake of inositol since enteral feeding intake 
was measured as the total amount fed over a day and not the amount fed at each occasion. In 
addition, as discussed in the Results section, the estimation of Ri will be from data from the 
period of time prior to the establishment of full enteral feeds.
As was used previously, the Pop-PK model for the initial IV administration period is a 1-
compartment IV infusion model with linear elimination(5). For this study the model was 
expanded to account for multiple administrations of inositol rather than a single 
administration used with the previous single-dose study. The model for serum concentrations 
resulting from endogenous synthesis and feeding of inositol and from IV administration is 
then
where Ci(t) is the serum concentration for the ith infant at time t, in hours, with time 
measured since the start of the first IV administration. The time of the kth IV administration 
to the ith infant is tDik and T is the duration of the infusion period common to all infants and 
administrations (1/3hr). The summations are over the IV administrations for the ith infant up 
to time t with n such that tDin ≤ t < tDin+1. Di is the dosage administered to the ith infant at 
each administration in mg of inositol per kg of body weight. Vi is the apparent volume of 
distribution. Finally, εit is the residual error at time t.
The between infant variability in the Pop-PK model parameters, Ri, Cli, and Vi, is modeled 
using random effect variables (uR, uCl and uv) that approximate the individual trajectory over 
time of each infant’s serum inositol concentration. The random effects are assumed to be 
normally distributed with means of 0 (zero) and variances and correlations that will be 
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estimated. For example, the clearance for the i-th infant is modeled as Cli = Cl × euCli where 
Cl is the fixed-effect common to all infants and uCli is the random effect unique to the i-th 
infant. Similarly for Ri and Vi. Thus, the three model parameters are log-normal. Individual 
specific parameter estimates were obtained as the conditional modes, or the maximum a 
posteriori, of the Bayes estimates of the parameters. The fixed effects, R, Cl and V, are the 
median, also modal, values of the parameters and are often called the typical values for the 
population from which each infant’s parameters are derived. The residual error, εit, is 
assumed to be uncorrelated with the random effects and normally distributed with mean 0 
(zero) and variance that is estimated from the data. The quality of fit of the Pop-PK model 
was judged by visual examination of plots of observed vs. individual predicted 
concentrations and of residuals vs. individual predicted concentrations.
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Figure 1. Consort Flow Sheet of Study Subjects
1Reason unknown. 2One infant identified as ineligible post-randomization; two infants 
died. 3One placebo subject incorrectly received 10mg/kg/day of inositol for 7 days before it 
was discovered and stopped and is considered to be part of the 10m/kg/day group only for 
the PK analysis. However, other data from this subject are analyzed, as randomized, with the 
placebo infants.
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Figure 2. Serum Inositol Levels
Mean±SD, by dose, clustered by days on study. Symbols: 80mg/kg/day = blue diamond, 
40mg/kg/day = green triangle, 10mg/kg/day = orange circle, placebo = red square. Panel A 
includes all samples; panel B values only while subjects were receiving IV doses; panel C 
values obtained only when subjects were receiving enteral dosing. Timed samples were 
collected within scheduled windows (see Methods), plus additional scavenged laboratory 
residual samples as available and if exact timing after the previous dose was known for the 
sample. For presentation, collection days are clustered in mean values to simplify display: 
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Study Day 0=baseline before 1st infusion; Day 2= 1st sample after 1st infusion; day 3=3rd 
study day; day 4=4–5d; day 6=6–7d; day 8=8–9d; day 10=10–11d; day 12=12–13d; day 
14=14–15d; day 16=16–18d; day 20=19–22d; day 24=23–26d; day 28=27–31d; day 
35d=32–38d; day 42=39–48d; day 56=49–63d; day 70=64–77d. Plotting only peak values, 
or only trough levels did not assist in displaying the data.
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Figure 3. Inositol Urine Losses
Inositol in the urine from each diaper (Concentration × Volume) was summed over 24hr to 
determine the urine losses, at weekly intervals. Data are mean±SD, and slightly offset for 
better visualization. Symbols: Square=placebo, circle=10mg/kg/day, triangle=40mg/kg/day 
and diamond=80mg/kg/day.
Phelps et al. Page 16
Pediatr Res. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Phelps et al. Page 17
Ta
bl
e 
1
B
as
el
in
e 
Ch
ar
ac
te
ris
tic
s a
nd
 D
em
og
ra
ph
ic
s
C
ha
ra
ct
er
ist
ic
St
at
ist
ic
s
In
os
ito
l D
os
e 
gr
o
u
p 
(m
g/k
g/d
ay
)
a
 
P-
va
lu
e
0 
(N
=3
5)
10
 (N
=2
9)
40
 (N
=3
0)
80
 (N
=2
8)
G
A
 (w
ee
ks
)
M
ea
n 
(S
D)
26
.5
 (0
.3)
26
.6
(0.
3)
26
.7
 (0
.3)
26
.7
 (0
.4)
0.
95
Lo
w
er
 G
A
 st
ra
tu
m
23
–2
6 
w
ee
k 
n 
(%
)
19
 (5
4%
)
15
 (5
2%
)
16
 (5
3%
)
14
 (5
0%
)
0.
99
B
irt
h 
w
ei
gh
t (
gra
ms
)
M
ea
n 
(S
D)
88
4 
(38
)
89
7 
(51
)
93
9 
(45
)
92
1 
(54
)
0.
83
H
ea
d 
ci
rc
um
fe
re
nc
e 
cm
M
ea
n 
(S
D)
23
.5
 (0
.4)
24
.1
 (0
.4)
25
.1
 (0
.5)
24
.6
 (0
.4)
0.
10
G
en
de
r
Fe
m
al
e
17
 (4
9%
)
15
 (5
2%
)
14
 (4
7%
)
16
 (5
7%
)
0.
87
R
ac
e
N
. A
m
er
ic
an
 N
at
iv
e
0
3 
(10
%)
0
0
0.
12
A
sia
n
0
1 
(3%
)
1 
(3%
)
0
B
la
ck
18
 (5
1%
)
15
 (5
2%
)
12
 (4
0%
)
13
 (4
6%
)
M
or
e 
Th
an
 O
nc
e 
Ra
ce
0
1 
(3%
)
0
0
W
hi
te
17
 (4
9%
)
9 
(31
%)
17
 (5
7%
)
15
 (5
4%
)
Et
hn
ic
ity
H
isp
an
ic
 o
r L
at
in
o
9 
(26
%)
3 
(10
%)
7 
(23
%)
8 
(29
%)
0.
35
A
nt
en
at
al
 st
er
oi
ds
32
 (9
1%
)
24
 (8
3%
)
24
 (8
0%
)
26
 (9
3%
)
0.
37
Ch
or
io
am
ni
on
iti
s
5 
(14
%)
4 
(14
%)
4 
(13
%)
3 
(11
%)
0.
97
Ce
sa
re
an
 D
el
iv
er
y
21
 (6
0%
)
16
 (5
5%
)
19
 (6
3%
)
14
 (5
0%
)
0.
75
Ea
rly
 o
ns
et
 se
ps
is
0
0
1 
(3%
)
0
0.
38
A
pg
ar
-
1 
m
in
ut
e
M
ed
ia
n 
(ra
ng
e)
3 
(1–
9)
5 
(1–
8)
3 
(1–
8)
5 
(1–
8)
0.
97
A
pg
ar
-
5 
m
in
ut
e
M
ed
ia
n 
(ra
ng
e)
7 
(1–
9)
8 
(1–
9)
7 
(1–
8)
7 
(3–
9)
0.
97
a P
-v
al
ue
s c
al
cu
la
te
d 
by
 te
sti
ng
 th
e 
nu
ll 
hy
po
th
es
is 
of
 e
qu
al
ity
 a
cr
os
s a
ll 
4 
tre
at
m
en
t g
ro
up
s u
sin
g 
A
N
OV
A
 te
ch
ni
qu
es
 fo
r c
on
tin
uo
us
 m
ea
su
re
s, 
M
an
te
l-H
ae
ns
ze
l m
ea
n 
sc
or
e 
te
sts
 u
sin
g 
m
od
ifi
ed
 ri
di
t s
co
re
s 
fo
r o
rd
in
al
 m
ea
su
re
s, 
an
d 
ch
i-s
qu
ar
e 
or
 F
ish
er
’s
 ex
ac
t t
es
t f
or
 n
om
in
al
 m
ea
su
re
s.
Pediatr Res. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Phelps et al. Page 18
Ta
bl
e 
2
N
ot
ab
le
 A
dv
er
se
 E
ve
n
ts
 th
ro
ug
h 
7 
da
ys
 p
os
t l
as
t d
os
e 
of
 st
ud
y 
dr
ug
C
at
eg
or
y
Pr
ef
er
re
d 
Te
rm
In
os
ito
l D
os
e 
gr
o
u
p 
(m
g/k
g/d
ay
)
P-
va
lu
es
0 
(N
=3
5)
10
 (N
=2
9)
40
 (N
=3
0)
80
 (N
=2
8)
IN
S 
vs
a
.
 
Pl
ac
eb
o
A
cr
o
ss
 D
os
es
b
A
ny
A
ny
33
 (9
4%
)
25
 (8
6%
)
27
 (9
0%
)
24
 (8
6%
)
0.
34
0.
65
Ca
rd
io
pu
lm
on
ar
y
Po
or
 p
er
fu
sio
n 
or
 h
yp
ot
en
sio
n
10
 (2
9%
)
7 
(24
%)
5 
(17
%)
7 
(25
%)
0.
48
0.
74
G
as
tro
in
te
sti
na
l
El
ev
at
ed
 li
v
er
 e
n
zy
m
es
1 
(3%
)
4 
(14
%)
1 
(3%
)
1 
(4%
)
0.
67
0.
33
H
em
at
ol
og
ic
A
ne
m
ia
16
 (4
6%
)
8 
(28
%)
14
 (4
7%
)
11
 (3
9%
)
0.
54
0.
42
N
eu
tro
pe
ni
a
3 
(9%
)
6 
(21
%)
3 
(10
%)
4 
(14
%)
0.
55
0.
52
Th
ro
m
bo
cy
to
pe
ni
a
3 
(9%
)
7 
(24
%)
5 
(17
%)
3 
(11
%)
0.
27
0.
34
Th
ro
m
bo
cy
to
sis
8(2
3%
)
10
 (3
4%
)
4 
(13
%)
6 
(21
%)
1.
00
0.
31
M
et
ab
ol
ic
H
yp
er
gl
yc
em
ia
8 
(23
%)
4 
(14
%)
4 
(13
%)
3 
(11
%)
0.
18
0.
63
O
th
er
7 
(20
%)
5 
(17
%)
4 
(13
%)
2 
(7%
)
0.
40
0.
53
R
en
al
Pr
ot
ei
nu
ria
3 
(9%
)
0 
(0%
)
0 
(0%
)
1 
(4%
)
0.
07
0.
21
O
lig
ur
ia
6 
(17
%)
7 
(24
%)
4 
(13
%)
4 
(14
%)
1.
00
0.
72
R
es
pi
ra
to
ry
A
pn
ea
11
 (3
1%
)
6 
(21
%)
10
 (3
3%
)
13
 (4
6%
)
1.
00
0.
23
a,
 b
P-
va
lu
es
 c
al
cu
la
te
d 
by
 te
sti
ng
 th
e 
nu
ll 
hy
po
th
es
is 
of
 e
qu
al
ity
 b
et
w
ee
n 
a p
la
ce
bo
 a
nd
 a
ll 
ac
tiv
e 
do
se
s c
om
bi
ne
d,
 a
nd
 b
se
pa
ra
te
ly
 a
cr
os
s a
ll 
4 
tre
at
m
en
t g
ro
up
s u
sin
g 
Fi
sh
er
’s
 ex
ac
t t
es
ts
.
Pediatr Res. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Phelps et al. Page 19
Ta
bl
e 
3
Cl
in
ic
al
 D
ia
gn
os
es
 T
hr
ou
gh
 H
os
pi
ta
l d
isc
ha
rg
e
D
os
e 
gr
o
u
p 
(m
g/k
g/d
ay
)
C
o-
m
or
bi
di
tie
s
0 
(N
=3
5)
10
 (N
=2
9)
40
 (N
=3
0)
80
 (N
=2
8)
P-
va
lu
eb
D
ea
th
 (t
hro
ug
h N
RN
 st
atu
sa )
6 
(17
%)
2 
(7%
)
6 
(20
%)
1 
(4%
)
0.
16
B
PD
 (O
2 
at
 3
6 
w
ee
ks
 P
M
A
 o
r p
rio
r d
ea
th
 fr
om
 B
PD
)
11
 (3
8%
)
7 
(26
%)
7 
(30
%)
8 
(30
%)
0.
81
R
es
pi
ra
to
ry
 D
ist
re
ss
 S
yn
dr
om
e
34
 (9
7%
)
29
 (1
00
%)
30
 (1
00
%)
27
 (9
6%
)
0.
72
PD
A
13
 (3
7%
)
14
 (4
8%
)
14
 (4
7%
)
10
 (3
6%
)
0.
68
PD
A
 (r
ec
eiv
ed
 su
rg
er
y)
3 
(9%
)
3 
(10
%)
1 
(3%
)
3 
(11
%)
0.
75
c  
IV
H
 (a
ny
)
13
 (3
8%
)
4 
(14
%)
10
 (3
4%
)
5 
(18
%)
0.
08
IV
H
 (g
rad
e I
II/
IV
)
10
 (2
9%
)
2 
(7%
)
6 
(21
%)
2 
(7%
)
0.
05
Se
iz
ur
es
 (R
x f
or 
>7
2 h
rs)
2 
(6%
)
0
1 
(3%
)
0
0.
62
Cy
sti
c 
ar
ea
s i
n 
pa
re
nc
hy
m
a 
(w
ith
in 
28
 da
ys
 of
 bi
rth
)
2 
(15
%)
0
1 
(10
%)
1 
(14
%)
1.
00
Se
ps
is 
(ea
rly
 on
set
)
0
0
1 
(3%
)
0
0.
71
Se
ps
is 
(la
te 
on
set
)
4 
(11
%)
6 
(21
%)
7 
(23
%)
5 
(18
%)
0.
63
d  
N
EC
 (s
us
pe
cte
d o
r p
rov
en
)
5 
(14
%)
1 
(3%
)
4 
(13
%)
1 
(4%
)
0.
28
N
EC
 (r
eq
uir
ing
 su
rge
ry
)
3 
(9%
)
0
2 
(7%
)
0
0.
17
Sp
on
ta
ne
ou
s e
 
G
I p
er
fo
ra
tio
n
2 
(6%
)
0
2 
(7%
)
1 
(4%
)
0.
72
Se
v
er
e 
RO
Pf
5/
27
(9%
)
3/
26
(12
%)
2/
24
 (8
%)
2/
23
(9%
)
0.
72
H
ea
rin
g 
sc
re
en
 fa
ile
d 
(ei
the
r e
ar)
1 
(4%
)
1 
(4%
)
4 
(20
%)
3 
(14
%)
0.
25
a N
RN
 st
at
us
 =
 N
eo
na
ta
l R
es
ea
rc
h 
N
et
w
o
rk
 d
ef
in
iti
on
: a
ge
 o
f e
ar
lie
st 
of
 d
ea
th
, d
isc
ha
rg
e,
 tr
an
sf
er
,
 
o
r 
12
0 
da
ys
 a
fte
r b
irt
h.
b P
-v
al
ue
s c
al
cu
la
te
d 
by
 te
sti
ng
 th
e 
nu
ll 
hy
po
th
es
is 
of
 e
qu
al
ity
 a
cr
os
s a
ll 
4 
tre
at
m
en
t g
ro
up
s u
sin
g 
Fi
sh
er
’s
 ex
ac
t t
es
ts
.
c I
V
H
 in
tra
v
en
tr
ic
ul
ar
 h
em
or
rh
ag
e,
d N
EC
 n
ec
ro
tiz
in
g 
en
te
ro
co
lit
is,
e G
I g
as
tr
oi
nt
es
tin
al
,
f R
et
in
op
at
hy
 o
f P
re
m
at
ur
ity
 m
ee
tin
g 
cr
ite
ria
 fo
r t
re
at
m
en
t o
r t
re
at
ed
 w
ith
 la
se
r, 
cr
yo
th
er
ap
y 
or
 a
nt
i-V
EG
F 
in
jec
tio
n a
mo
ng
 th
ose
 w
ho
 su
rvi
v
ed
 fo
r e
v
al
ua
tio
n.
 W
ith
 th
e 
6 
ad
jud
ica
ted
 RO
P 
ou
tc
om
es
 
in
cl
ud
ed
, r
at
es
 w
er
e 
sim
ila
r (
17
%,
 11
%,
 8%
 an
d 8
% 
res
pe
cti
v
el
y).
 T
he
 de
no
mi
na
tor
s f
or 
BP
D 
are
 al
l e
nro
lle
d.
Pediatr Res. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Phelps et al. Page 20
Table 4
Population pharmacokinetic parameter estimates for a typical infant (fixed effects)
Parameter Units
Estimates (Standard Error)
Single IV 
Administration Dataset
Multiple IV 
Administration Dataset Combined Dataset
Model Parameters
V – volume l/kg 0.5115 (0.0345) 0.6572 (0.0707) 0.5610 (0.0341)
Cl – clearance (l/kg)/h 0.0679 (0.0064) 0.0577 (0.0061) 0.0616 (0.0048)
R – endogenous infusion rate (mg/kg)/h 2.666 (0.2762) 2.369 (0.3151) 2.449 (0.2336)
Standard deviation of residual error mg/l 18.71 (1.048) 24.77 (0.971) 22.96 (0.739)
Derived Values
k – elimination rate (=Cl/V) 1/h 0.1327 (0.0154) 0.0878 (0.0137) 0.1098 (0.0109)
t1/2 – half=life (=.693/k) h 5.22 (0.605) 7.90 (1.229) 6.31 (0.631)
E – concentration due to endogenous infusion 
(=R/Cl) mg/l 39.26 (1.655) 41.06 (1.777) 40.71 (1.255)
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Table 5
Population pharmacokinetic random effect variances and correlations for the combined dataset
Volume (uV) Clearance (uCl) Endogenous infusion rate (uR)
Volume (uV) 0.1181 -- --
Clearance (uCl) 0.0a 0.3508 --
Endogenous infusion rate (uR) 0.0a 0.9349 0.4899
Random effect variances are displayed on the diagonal and correlations between the random effects on the off diagonal.
aCorrelation set to 0.0 (zero) based on review of plots of uVi vs. uCli and uVi vs. uRi.
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